PATENT CLAIM ANALYSIS

Application Number: 15947231
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["424", "093700"]

Abstract:
Provided are uses of allogeneic interstitial vessel-layer cells and allogeneic mesenchymal progenitor cells in the preparation of a pharmaceutical composition for preventing or treating osteoarthritis (OA). Also provided is a pharmaceutical composition containing the allogeneic interstitial vessel-layer cells and the allogeneic mesenchymal progenitor cells.

Claim (Index 22):
The method of  claim 17 , wherein, said allogeneic mesenchymal progenitor cells have one or more features selected from the following group:\n (v) less than 2% of the cells having surface antigen HLA-DR; (vi) less than 2% of the cells having surface antigen Actin; (vii) less than 2% of the cells having surface antigen CD34; (viii) less than 2% of the cells having surface antigen CD45; (ix) less than 2% of the cells having surface antigen CD14.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.6
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14765755', '13905526', '13691349', '12091018', '13989708']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7303830722322295
- 35 USC 102 Novelty (BERT): 0.6046125793256519
- Combined Prediction Score: 0.7178060229415718
- Mean Citation Score: 303.1604920000001
- Max Citation Score: 559.7753
- Similarity Product: 463.1672747208596

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test